
Title:
Akathisia
Text:
Movement disorder involving a feeling of inner restlessness


Medical condition.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}AkathisiaOther namesAcathisiaPlay mediaCommon sign of akathisiaSpecialtyNeurology, psychiatrySymptomsFeelings of restlessness, inability to stay still, uneasy[1]ComplicationsViolence or suicidal thoughts[2]DurationShort- or long-term[2]CausesAntipsychotics, selective serotonin reuptake inhibitors, metoclopramide, reserpine[2]Diagnostic methodBased on symptoms[2]Differential diagnosisAnxiety, tic disorders, tardive dyskinesia, dystonia, medication-induced parkinsonism, restless leg syndrome[2][3]TreatmentReduce or switch antipsychotics, correct iron deficiency[2]MedicationDiphenhydramine, trazodone, benzodiazepines, benztropine, mirtazapine, beta blockers[4][2]FrequencyRelatively common[4]
Akathisia is a movement disorder[5] characterized by a subjective feeling of inner restlessness accompanied by mental distress and an inability to sit still.[6][4] Usually, the legs are most prominently affected.[2] Those affected may fidget, rock back and forth, or pace,[7] while some may just have an uneasy feeling in their body.[2] The most severe cases may result in aggression, violence or suicidal thoughts.[2]
Antipsychotic medication, particularly the first generation antipsychotics, are a leading cause.[4][7] Other agents responsible for this side-effect may also include selective serotonin reuptake inhibitors, metoclopramide, and reserpine.[2] It may also occur upon stopping antipsychotics.[2] The underlying mechanism is believed to involve dopamine.[2] Diagnosis is based on the symptoms.[2] It differs from restless leg syndrome in that akathisia is not associated with sleeping.[2]
Treatment may include switching to an antipsychotic with a lower risk of the condition.[2] The antidepressant mirtazapine has demonstrated benefit,[5] and there is tentative evidence of benefit for diphenhydramine, trazodone, benzatropine and beta blockers.[2][4]
The term was first used by Czech neuropsychiatrist Ladislav Haškovec, who described the phenomenon in 1901.[1] It is from Greek a-, meaning "not", and καθίζειν kathízein, meaning "to sit", or in other words an "inability to sit".[2]

Contents

1 Classification
2 Signs and symptoms
3 Causes

3.1 Medication-induced


4 Diagnosis
5 Treatment
6 Epidemiology
7 History
8 See also
9 Notes
10 References
11 External links



Classification[edit]
Akathisia is usually grouped as a medication-induced movement disorder but is also seen to be a neuropsychiatric concern as it can be experienced purely subjectively with no apparent movement abnormalities.[2] Akathisia is generally associated with antipsychotics but it was already described in Parkinson's disease, and other neuropsychiatric disorders.[5] It also presents with the use of non-psychiatric medications, including calcium channel blockers, antibiotics, anti-nausea and anti-vertigo drugs.[5]

Signs and symptoms[edit]
Symptoms of akathisia are often described in vague terms such as feeling nervous, uneasy, tense, twitchy, restless, and an inability to relax.[1] Reported symptoms also include insomnia, a sense of discomfort, motor restlessness, marked anxiety, and panic.[8] Symptoms have also been said to resemble symptoms of neuropathic pain that are similar to fibromyalgia and restless legs syndrome.[9] When due to psychiatric drugs, the symptoms are side effects that usually disappear quickly and remarkably when the medication is reduced or stopped. However, tardive akathisia which has a late onset, may go on long after the medication is discontinued, for months and sometimes years.[10]
When misdiagnosis occurs in antipsychotic-induced akathisia, more antipsychotic may be prescribed, potentially worsening the symptoms.[7][11] If symptoms are not recognised and identified akathisia can increase in severity and lead to suicidal thoughts, aggression and violence.[1][2]
Visible signs of akathisia include repetitive movements such as crossing and uncrossing the legs, and constant shifting from one foot to the other.[1] Other noted signs are rocking back and forth, fidgeting and pacing.[7] However not all observable restless motion is akathisia. For example, mania, agitated depression, and attention deficit hyperactivity disorder may look like akathisia, but the movements feel voluntary and not due to restlessness.[12]
Jack Henry Abbott, who was diagnosed with akathisia, described the sensation in 1981 as: “You ache with restlessness, so you feel you have to walk, to pace. And then as soon as you start pacing, the opposite occurs to you; you must sit and rest. Back and forth, up and down you go … you cannot get relief …“[13]

Causes[edit]
Medication-induced[edit]

Medication related causes of akathisia


Category
Examples


Antipsychotics[14]
Haloperidol, amisulpride, risperidone, aripiprazole, lurasidone, ziprasidone


SSRIs[15]
Fluoxetine,[15] paroxetine,[8] citalopram, sertraline[16]


Antidepressants
Venlafaxine, tricyclics, trazodone, and mirtazapine[17]


Antiemetics
Metoclopramide, prochlorperazine, and promethazine


Drug withdrawal
Antipsychotic withdrawal[2]


Serotonin syndrome[18]
Harmful combinations of psychotropic drugs

Medication-induced akathisia is termed acute akathisia and is frequently associated with the use of antipsychotics.[10] Antipsychotics block dopamine receptors, but the pathophysiology is poorly understood. Additionally, drugs with successful therapeutic effects in the treatment of medication-induced akathisia have provided additional insight into the involvement of other transmitter systems. These include benzodiazepines, β-adrenergic blockers, and serotonin antagonists.[19] Another major cause of the syndrome is the withdrawal observed in drug-dependent individuals. Since dopamine deficiency (or disruptions in dopamine signalling) appears to play an important role in the development of RLS, a form of akathisia focused in the legs,[medical citation needed] the sudden withdrawal or rapidly decreased dosage of drugs which increase dopamine signalling may create similar deficits of the chemical which mimic dopamine antagonism and thus can precipitate RLS. This is why sudden cessation of opioids, cocaine, serotonergics, and other euphoria-inducing substances commonly produce RLS as a side-effect.[19]
Akathisia involves increased levels of the neurotransmitter norepinephrine, which is associated with mechanisms that regulate aggression, alertness, and arousal.[20] It has been correlated with Parkinson's disease and related syndromes, and descriptions of akathisia predate the existence of pharmacologic agents.[5]
Akathisia can be miscoded in side effect reports from antidepressant clinical trials as "agitation, emotional lability, and hyperkinesis (overactivity)"; misdiagnosis of akathisia as simple motor restlessness occurred, but was more properly classed as dyskinesia.[medical citation needed][8]

Diagnosis[edit]
The presence and severity of akathisia can be measured using the Barnes Akathisia Scale,[21][22] which assesses both objective and subjective criteria.[21] Precise assessment of akathisia is problematic, as there are various types making it difficult to differentiate from disorders with similar symptoms.[5]
The primary distinguishing features of akathisia in comparison with other syndromes are primarily subjective characteristics, such as the feeling of inner restlessness and tension.[23][24] Akathisia can commonly be mistaken for agitation secondary to psychotic symptoms or mood disorder, antipsychotic dysphoria, restless legs syndrome (RLS), anxiety, insomnia, drug withdrawal states, tardive dyskinesia, or other neurological and medical conditions.[19]
The controversial diagnosis of "pseudoakathisia" is sometimes given.[1]

Treatment[edit]
Acute akathisia induced by medication,[10] often antipsychotics, is treated by reducing or discontinuing the medication.[2][25] Low doses of the antidepressant mirtazapine may be of help.[5][26] Benzodiazepines, such as lorazepam, beta blockers such as propranolol, anticholinergics such as benztropine, and serotonin antagonists such as cyproheptadine may also be of help in treating acute akathisia but are much less effective for treating chronic akathisia.[25] Vitamin B, and iron supplementation if deficient, may be of help.[2][4]

Epidemiology[edit]
This article needs to be updated. Please help update this article to reflect recent events or newly available information.  (July 2020)
As of 2007, published epidemiological data for akathisia was mostly limited to studies before the availability of second-generation antipsychotics.[25] Prevalence rates may be lower for modern treatment as second-generation antipsychotics carry a lower risk of akathisia.[25]
Approximately one out of four individuals treated with first-generation antipsychotics have akathisia.[5]

History[edit]
The term was first used by Czech neuropsychiatrist Ladislav Haškovec, who described the phenomenon in a non-medication induced presentation in 1901.[27][1]
Reports of medication-induced akathisia from chlorpromazine appeared in 1954.[a] Later in 1960 there were reports of akathisia in response to phenothiazines (a related drug).[1] Akathisia is classified as an extrapyramidal side effect along with other movement disorders that can be caused by antipsychotics.[1]
In the former Soviet Union, akathisia-inducing drugs were allegedly used as a form of torture. Haloperidol, an antipsychotic medication, was used to induce intense restlessness and Parkinson's-type symptoms in prisoners.[29]
In 2020 clinical psychologist and professor of psychology Jordan Peterson was diagnosed with akathisia after being treated for insomnia and depression with Benzodiazepines that was associated with an autoimmune disorder and was subsequently treated in Russia.[30][31][32]

See also[edit]
Stimming
Notes[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ "In 1954,  two separate researchers,  Professor Hans Steck of Lausanne,  and German psychiatrist Hans Joachim Haase provided the first unambiguous descriptions of a  syndrome of abnormally reduced and restricted movement that was associated with chlorpromazine.  [...] They also described the drug-induced agitation known as akathisia (Hasse, 1954; Steck, 1954)."[28] : 40 


References[edit]


^ a b c d e f g h i .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}Salem H, Nagpal C, Pigott T, Teixeira AL (2017). "Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges". Curr Neuropharmacol (Review). 15 (5): 789–798. doi:10.2174/1570159X14666161208153644. PMC 5771055. PMID 27928948.

^ a b c d e f g h i j k l m n o p q r s t u v w Lohr, JB; Eidt, CA; Abdulrazzaq Alfaraj, A; Soliman, MA (December 2015). "The clinical challenges of akathisia". CNS Spectrums (Review). 20 Suppl 1: 1–14, quiz 15–6. doi:10.1017/S1092852915000838. PMID 26683525. S2CID 4253429.

^ Kaufman, David Myland; Milstein, Mark J. (2012). Kaufman's Clinical Neurology for Psychiatrists E-Book. Elsevier Health Sciences. p. 429. ISBN 978-1455740048.

^ a b c d e f Laoutidis, ZG; Luckhaus, C (May 2014). "5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis". The International Journal of Neuropsychopharmacology (Review). 17 (5): 823–32. doi:10.1017/S1461145713001417. PMID 24286228.

^ a b c d e f g h Poyurovsky M, Weizman A (June 2020). "Treatment of Antipsychotic-Induced Akathisia: Role of Serotonin 5-HT2a Receptor Antagonists". Drugs (Review). 80 (9): 871–882. doi:10.1007/s40265-020-01312-0. PMID 32385739. S2CID 218541032.

^ Forcen, FE; Matsoukas, K; Alici, Y (February 2016). "Antipsychotic-induced akathisia in delirium: A systematic review". Palliative & Supportive Care (Review). 14 (1): 77–84. doi:10.1017/S1478951515000784. PMC 5516628. PMID 26087817.

^ a b c d Thomas, JE; Caballero, J; Harrington, CA (2015). "The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis". Current Neuropharmacology (Review). 13 (5): 681–91. doi:10.2174/1570159x13666150115220221. PMC 4761637. PMID 26467415.

^ a b c Healy, David; Herxheimer, Andrew; Menkes, David B. (2006). "Antidepressants and Violence: Problems at the Interface of Medicine and Law". PLOS Medicine (Review). 3 (9): e372. doi:10.1371/journal.pmed.0030372. PMC 1564177. PMID 16968128.

^ Sachdev, Perminder (2006). Akathisia and Restless Legs. Cambridge University Press. p. 299. ISBN 978-0-521-03148-6.

^ a b c Diagnostic and statistical manual of mental disorders : DSM-5 (5th ed.). American Psychiatric Association. 2013. pp. 711–712. ISBN 9780890425541.

^ Szabadi, E (1986). "Akathisia—or not sitting". BMJ (editorial). 292 (6527): 1034–5. doi:10.1136/bmj.292.6527.1034. PMC 1340104. PMID 2870759.

^ Forcen FE (January 2015). "Akathisia: Is restlessness a primary condition or an adverse drug effect?". Current Psychiatry. 14 (1): 14–18 – via mededge.

^ Jack Henry Abbot In the Belly of the Beast (1981/1991). Vintage Books, 35–36. Quoted in Robert Whitaker, Mad in America (2002, ISBN 0-7382-0799-3), 187.

^ Diaz, Jaime (1996). How Drugs Influence Behavior. Englewood Cliffs: Prentice Hall.[page needed]

^ a b Hansen, Lars (2003). "Fluoxetine Dose-Increment Related Akathisia in Depression: Implications for Clinical Care, Recognition and Management of Selective Serotonin Reuptake Inhibitor-Induced Akathisia". Journal of Psychopharmacology. 17 (4): 451–2. doi:10.1177/0269881103174003. PMID 14870959. S2CID 40974047.

^ Altshuler, L. L.; Pierre, J. M.; Wirshing, W. C.; Ames, D. (August 1994). "Sertraline and akathisia". Journal of Clinical Psychopharmacology. 14 (4): 278–279. doi:10.1097/00004714-199408000-00010. ISSN 0271-0749. PMID 7962686.

^ "Remeron (Mirtazapine) Drug Information". RxList. Retrieved 28 March 2016.

^ Dunkley, E.J.C.; Isbister, G.K.; Sibbritt, D.; Dawson, A.H.; Whyte, I.M. (18 August 2003). "The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity". QJM. 96 (9): 635–642. doi:10.1093/qjmed/hcg109. PMID 12925718.

^ a b c Kane, John M.; Fleischhacker, Wolfgang W.; Hansen, Lars; Perlis, Roy; Pikalov a, Andrei; Assunção-Talbott, Sheila (2009). "Akathisia: An Updated Review Focusing on Second-Generation Antipsychotics". The Journal of Clinical Psychiatry (Review). 70 (5): 627–43. doi:10.4088/JCP.08r04210. PMID 19389331.

^ Marc E. Agronin; Gabe J. Maletta (2006). "Chapter 14: Pharmacotherapy in the Elderly". Principles and Practice of Geriatric Psychiatry (illustrated ed.). Lippincott Williams & Wilkins. p. 215. ISBN 978-0-7817-4810-0. Retrieved 23 November 2013.

^ a b Barnes, T. R. (1989). "A rating scale for drug-induced akathisia". The British Journal of Psychiatry. 154 (5): 672–6. doi:10.1192/bjp.154.5.672. PMID 2574607.

^ Barnes, Thomas R. E. (2003). "The Barnes Akathisia Rating Scale–Revisited". Journal of Psychopharmacology. 17 (4): 365–70. doi:10.1177/0269881103174013. PMID 14870947. S2CID 29435046.

^ Kim, JH; Byun, HJ (2003). "Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects". Clinical Neuropharmacology. 26 (6): 312–6. doi:10.1097/00002826-200311000-00010. PMID 14646611. S2CID 23393707.

^ Practitioners, The Royal Australian College of General. "RACGP - Beyond anxiety and agitation: A clinical approach to akathisia". www.racgp.org.au. Retrieved 12 August 2020.

^ a b c d Bratti IM, Kane JM, Marder SR (November 2007). "Chronic restlessness with antipsychotics". Am J Psychiatry. 164 (11): 1648–54. doi:10.1176/appi.ajp.2007.07071150. PMID 17974927.

^ Perry LA, Ramson D, Stricklin S (May 2018). "Mirtazapine adjunct for people with schizophrenia". Cochrane Database Syst Rev (Review). 2018 (5): CD011943. doi:10.1002/14651858.CD011943.pub2. PMC 6494505. PMID 29802811.

^ Mohr, P; Volavka, J (December 2002). "Ladislav Haskovec and akathisia: 100th anniversary". The British Journal of Psychiatry. 181 (6): 537. doi:10.1192/bjp.181.6.537-a. PMID 12456534.

^ J. Moncrieff (15 September 2013). The Bitterest Pills: The Troubling Story of Antipsychotic Drugs. Springer. ISBN 978-1-137-27744-2.

^ *Darius Rejali (8 June 2009). Torture and Democracy. Princeton University Press. pp. 392–. ISBN 978-1-4008-3087-9.

^ Why was Jordan Peterson placed in a medically induced coma? What we know about benzodiazepines and treatment Published 11 February 2020 by the National Post

^ Jordan Peterson says he was suicidal, addicted to benzos

^ Mikhaila Peterson's Response to The Times Article (and subsequent articles)


External links[edit]
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}ClassificationDICD-10: G21.1ICD-9-CM: 781.0, 333.99MeSH: D011595DiseasesDB: 32479External resourceseMedicine: neuro/362 emerg/338
.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteDiseases of the nervous system, primarily CNSInflammationBrain
Encephalitis
Viral encephalitis
Herpesviral encephalitis
Limbic encephalitis
Encephalitis lethargica
Cavernous sinus thrombosis
Brain abscess
Amoebic
Brain and spinal cord
Encephalomyelitis
Acute disseminated
Meningitis
Meningoencephalitis
Brain/encephalopathyDegenerativeExtrapyramidal andmovement disorders
Basal ganglia disease
Parkinsonism
PD
Postencephalitic
NMS
PKAN
Tauopathy
PSP
Striatonigral degeneration
Hemiballismus
HD
OA
Dyskinesia
Dystonia
Status dystonicus
Spasmodic torticollis
Meige's
Blepharospasm
Athetosis
Chorea
Choreoathetosis
Myoclonus
Myoclonic epilepsy
Akathisia
Tremor
Essential tremor
Intention tremor
Restless legs
Stiff-person
Dementia
Tauopathy
Alzheimer's
Early-onset
Primary progressive aphasia
Frontotemporal dementia/Frontotemporal lobar degeneration
Pick's
Dementia with Lewy bodies
Posterior cortical atrophy
Vascular dementia
Mitochondrial disease
Leigh syndrome
Demyelinating
Autoimmune
Inflammatory
Multiple sclerosis
For more detailed coverage, see Template:Demyelinating diseases of CNS
Episodic/paroxysmalSeizures and epilepsy
Focal
Generalised
Status epilepticus
For more detailed coverage, see Template:Epilepsy
Headache
Migraine
Cluster
Tension
For more detailed coverage, see Template:Headache
Cerebrovascular
TIA
Stroke
For more detailed coverage, see Template:Cerebrovascular diseases
Other
Sleep disorders
For more detailed coverage, see Template:Sleep
CSF
Intracranial hypertension
Hydrocephalus
Normal pressure hydrocephalus
Choroid plexus papilloma
Idiopathic intracranial hypertension
Cerebral edema
Intracranial hypotension
Other
Brain herniation
Reye syndrome
Hepatic encephalopathy
Toxic encephalopathy
Hashimoto's encephalopathy
Static Encephalopathy
Both/eitherDegenerativeSA
Friedreich's ataxia
Ataxia–telangiectasia
MND
UMN only:
Primary lateral sclerosis
Pseudobulbar palsy
Hereditary spastic paraplegia
LMN only:
Distal hereditary motor neuronopathies
Spinal muscular atrophies
SMA
SMAX1
SMAX2
DSMA1
Congenital DSMA
Spinal muscular atrophy with lower extremity predominance (SMALED)
SMALED1
SMALED2A
SMALED2B
SMA-PCH
SMA-PME
Progressive muscular atrophy
Progressive bulbar palsy
Fazio–Londe
Infantile progressive bulbar palsy
both:
Amyotrophic lateral sclerosis






